Health Technology Assessment (HTA) is entering a new era as agencies explore the role of artificial intelligence (AI) in transforming evidence review and decision-making, and facilitating a move towards a “living” HTA model. Technology developers are equally being challenged to move beyond traditional static submissions toward continuously updated evidence packages, supported by AI.

AI is helping teams with more efficient evidence generation, earlier strategic planning, and stronger alignment with HTA, regulatory, and payer expectations, particularly in the context of initiatives such as the EU Joint Clinical Assessment (JCA).

However, adoption of new methods and ways of working also bring important questions around transparency, explainability, auditability, and regulatory acceptance.

In this webinar, Cytel experts will explore how AI is reshaping HTA and facilitating a move towards “living” HTA. They will also share practical insights on integrating AI into submission strategies, building regulatory, HTA, and payer confidence, and evolving organizational capabilities to meet changing expectations.

Key Topics

• The evolving acceptance of AI by HTA bodies
• The shift from static dossiers to “living” evidence submissions and assessment
• AI for early HTA strategy, including EU JCA landscaping and PICO simulation
• Ensuring explainability and transparency of AI in HTA contexts
• The evolving role of HEOR and market access teams in an AI-enabled environment

Speakers

• Manuel Cossio, Head of AI Solutions, Real-World Evidence, Value, and Access
• Dalia Dawoud, Research Principal, HTA Policy and Strategy